25 news items
Danish pharmaceutical giant Novo Nordisk, the maker of Ozempic and Wegovy, has announced it will shorten its public-facing brand to simply “Novo” as part of a broader corporate culture overhaul,…
The long-running legal battle between Novo Nordisk and South African compounding pharmacy iDexis has taken another turn, after a Pretoria High Court judge refused the pharmacy’s bid to appeal an…
Aspen Pharmacare, Eli Lilly’s exclusive distributor for Mounjaro across sub-Saharan Africa, says it expects the weight-loss and diabetes drug to generate more than R2 billion (about $124 million) in sales…
Despite the clinical promise of GLP-1 receptor agonists such as semaglutide and tirzepatide, at least one South African healthcare leader is cautioning that the drugs cannot, on their own, fix…
South Africa’s GLP-1 market has entered a new phase: Sun Pharma’s local subsidiary Ranbaxy has launched Semagard, the country’s first generic semaglutide injection, at a price roughly 18.5% below Novo…
A new experimental weight-loss pill has posted strong results in early clinical testing, adding another contender to the fast-growing race for an effective oral alternative to injectable GLP-1 drugs like…
Novo Nordisk is launching an authorised copy of Ozempic in South Africa on 27 July 2026 — the first authorised semaglutide copy registered by SAHPRA. It’s called Extensior. Unlike a…
Pretoria compounding pharmacy iDexis, trading as Sentra Pharmacy, has applied for leave to appeal the High Court order that stopped it from manufacturing and selling compounded medicines containing semaglutide.
South Africa's medicines regulator says weight-loss injections are now the single biggest category in its investigations into illicit medicine sales. Criminal syndicates are exploiting demand for GLP-1 medicines by selling…
Generic and lower-cost semaglutide options from Sun Pharma and Novo Nordisk/Acino are entering the South African market just as regulators intensify enforcement against unregistered compounded products. Here is what it…
Durban-based Aspen Pharmacare has received regulatory approval from Health Canada to distribute Aspen-Semaglutide, a generic alternative to Novo Nordisk's Ozempic. South Africa will manufacture the multi-dose pens while a French…
South Africa’s health products regulator (SAHPRA) said on Tuesday, July 21, that it is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and…
Register free to read every article, receive our weekly digest and submit questions to our expert panel.
Already registered? Sign in here
